|
Phenotype
|
Fish
|
Conditions
|
Figures
|
|
head ccnk expression increased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 3.
from Hancock et al., 2026
|
|
head krt17 expression decreased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 4.
from Hancock et al., 2026
|
|
head reep1 expression increased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 2.
from Hancock et al., 2026
|
|
head clrn2 expression decreased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 3.
from Hancock et al., 2026
|
|
head myh7 expression decreased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 4.
from Hancock et al., 2026
|
|
head nfatc2b expression increased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 2.
from Hancock et al., 2026
|
|
antigen processing and presentation of endogenous peptide antigen via MHC class I decreased occurrence, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 2.
from Hancock et al., 2026
|
|
head lsm8 expression increased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 4.
from Hancock et al., 2026
|
|
head capgb expression decreased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 3. ,
Fig. 4.
from Hancock et al., 2026
|
|
head aplp2 expression decreased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 4.
from Hancock et al., 2026
|
|
head trim2b expression increased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 2.
from Hancock et al., 2026
|
|
head mphosph10 expression decreased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 4.
from Hancock et al., 2026
|
|
pre-mRNA catabolic process decreased occurrence, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 2.
from Hancock et al., 2026
|
|
serotonin receptor signaling pathway increased occurrence, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 3.
from Hancock et al., 2026
|
|
G1/S transition of mitotic cell cycle decreased occurrence, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 2.
from Hancock et al., 2026
|
|
cell cycle checkpoint signaling decreased occurrence, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 2.
from Hancock et al., 2026
|
|
head rgra expression decreased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 2.
from Hancock et al., 2026
|
|
head rdh5 expression decreased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 4.
from Hancock et al., 2026
|
|
head pkhd1l1.1 expression decreased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 3.
from Hancock et al., 2026
|
|
striated muscle contraction decreased occurrence, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 3.
from Hancock et al., 2026
|
|
head tgm5l expression increased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 2.
from Hancock et al., 2026
|
|
DNA biosynthetic process decreased occurrence, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 2.
from Hancock et al., 2026
|
|
head mnx1 expression decreased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 3.
from Hancock et al., 2026
|
|
protein neddylation decreased occurrence, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 2.
from Hancock et al., 2026
|
|
head gfi1ab expression decreased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 3.
from Hancock et al., 2026
|
|
head slc7a2 expression decreased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 4.
from Hancock et al., 2026
|
|
head tas2r200.1 expression increased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 2.
from Hancock et al., 2026
|
|
head scinlb expression decreased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 3.
from Hancock et al., 2026
|
|
phototransduction, visible light increased occurrence, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 3.
from Hancock et al., 2026
|
|
head nefla expression decreased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 4.
from Hancock et al., 2026
|
|
head adisspa expression decreased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 4.
from Hancock et al., 2026
|
|
mitotic prometaphase decreased occurrence, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 2.
from Hancock et al., 2026
|
|
head dpp6a expression decreased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 4.
from Hancock et al., 2026
|
|
head chd7 expression decreased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 3. ,
Fig. 4.
from Hancock et al., 2026
|
|
head dkc1 expression decreased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 4.
from Hancock et al., 2026
|
|
head gpr37l1a expression increased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 3.
from Hancock et al., 2026
|
|
head scin expression increased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 2.
from Hancock et al., 2026
|
|
head c9 expression decreased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 4.
from Hancock et al., 2026
|
|
estrogen receptor signaling pathway decreased occurrence, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 2.
from Hancock et al., 2026
|
|
GCN2-mediated signaling decreased occurrence, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 4.
from Hancock et al., 2026
|
|
head phex expression decreased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 3.
from Hancock et al., 2026
|
|
head adgra2 expression increased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 2.
from Hancock et al., 2026
|
|
head pdyn expression increased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 2.
from Hancock et al., 2026
|
|
head npas4a expression increased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 2.
from Hancock et al., 2026
|
|
swimming behavior decreased process quality, abnormal
|
chd7ncu101/ncu101
|
high light intensity
|
Fig. 6.
from Hancock et al., 2026
|
|
sensory perception of sound decreased process quality, abnormal
|
chd7ncu101/ncu101
|
acoustic radiation
|
Fig. 6.
from Hancock et al., 2026
|
|
head vcana expression decreased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 3.
from Hancock et al., 2026
|
|
head gsx1 expression decreased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 2.
from Hancock et al., 2026
|
|
nuclear-transcribed mRNA catabolic process, nonsense-mediated decay decreased occurrence, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 4.
from Hancock et al., 2026
|
|
head capga expression increased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 2.
from Hancock et al., 2026
|
|
calcium-mediated signaling decreased occurrence, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 3.
from Hancock et al., 2026
|
|
mitotic metaphase decreased occurrence, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 2.
from Hancock et al., 2026
|
|
head pcsk9 expression increased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 3.
from Hancock et al., 2026
|
|
head grk1a expression increased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 4.
from Hancock et al., 2026
|
|
head myhz2 expression decreased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 4.
from Hancock et al., 2026
|
|
head pcyt1aa expression increased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 3.
from Hancock et al., 2026
|
|
SRP-dependent cotranslational protein targeting to membrane decreased occurrence, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 4.
from Hancock et al., 2026
|
|
head crybb2 expression decreased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 3.
from Hancock et al., 2026
|
|
Roundabout signaling pathway decreased occurrence, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 4.
from Hancock et al., 2026
|
|
head qtman expression decreased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 2.
from Hancock et al., 2026
|
|
swimming behavior decreased process quality, abnormal
|
chd7ncu101/ncu101
|
acoustic radiation
|
Fig. 6.
from Hancock et al., 2026
|
|
head eif5b expression decreased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 4.
from Hancock et al., 2026
|
|
head ptn expression increased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 3.
from Hancock et al., 2026
|
|
head icn expression decreased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 4.
from Hancock et al., 2026
|
|
rRNA processing decreased occurrence, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 4.
from Hancock et al., 2026
|
|
head smc1a expression increased amount, abnormal
|
chd7ncu101/ncu101
|
standard conditions
|
Fig. 4.
from Hancock et al., 2026
|
|
sensory perception of light stimulus decreased process quality, abnormal
|
chd7ncu101/ncu101
|
high light intensity
|
Fig. 6.
from Hancock et al., 2026
|
|
pericardium increased size, abnormal
|
chd7ncu101/ncu101 (TL)
|
standard conditions
|
Fig. 1
from Hodorovich et al., 2023
|
|
swim bladder uninflated, abnormal
|
chd7ncu101/ncu101 (TL)
|
standard conditions
|
Fig. 1
from Hodorovich et al., 2023
|
|
visual learning process characteristic, abnormal
|
chd7ncu101/ncu101 (TL)
|
altered light dark cycle
|
Fig. 4
from Hodorovich et al., 2023
|
|
lapillus decreased amount, abnormal
|
chd7ncu101/ncu101 (TL)
|
standard conditions
|
Fig. 1
from Hodorovich et al., 2023
|
|
startle response process characteristic, abnormal
|
chd7ncu101/ncu101 (TL)
|
acoustic radiation
|
Fig. 2 ,
Fig. 3
from Hodorovich et al., 2023
|
|
lapillus decreased size, abnormal
|
chd7ncu101/ncu101 (TL)
|
standard conditions
|
Fig. 1
from Hodorovich et al., 2023
|
|
embryonic cranial skeleton morphogenesis disrupted, abnormal
|
chd7ncu101/ncu101 (TL)
|
standard conditions
|
Fig. 1
from Hodorovich et al., 2023
|
|
cranium morphology, abnormal
|
chd7ncu101/ncu101 (TL)
|
standard conditions
|
Fig. 1
from Hodorovich et al., 2023
|
|
otolith morphology, abnormal
|
chd7ncu101/ncu101 (TL)
|
acoustic radiation
|
Fig. 3
from Hodorovich et al., 2023
|
|
visual behavior process characteristic, abnormal
|
chd7ncu101/ncu101 (TL)
|
altered light dark cycle
|
Fig. 4
from Hodorovich et al., 2023
|
|
whole organism decreased life span, abnormal
|
chd7ncu101/ncu101 (TL)
|
standard conditions
|
Fig. 1
from Hodorovich et al., 2023
|
|
otolith morphology, abnormal
|
chd7ncu101/ncu101 (TL)
|
standard conditions
|
Fig. 1
from Hodorovich et al., 2023
|
|
sagitta decreased amount, abnormal
|
chd7ncu101/ncu101 (TL)
|
standard conditions
|
Fig. 1
from Hodorovich et al., 2023
|
|
nonassociative learning disrupted, abnormal
|
chd7ncu101/ncu101 (TL)
|
acoustic radiation
|
Fig. 2
from Hodorovich et al., 2023
|
|
pericardium increased size, abnormal
|
chd7ncu101/+ (TL)
|
standard conditions
|
Fig. 1
from Hodorovich et al., 2023
|
|
swim bladder uninflated, abnormal
|
chd7ncu101/+ (TL)
|
standard conditions
|
Fig. 1
from Hodorovich et al., 2023
|
|
lapillus decreased amount, abnormal
|
chd7ncu101/+ (TL)
|
standard conditions
|
Fig. 1
from Hodorovich et al., 2023
|
|
lapillus decreased size, abnormal
|
chd7ncu101/+ (TL)
|
standard conditions
|
Fig. 1
from Hodorovich et al., 2023
|
|
cranium morphology, abnormal
|
chd7ncu101/+ (TL)
|
standard conditions
|
Fig. 1
from Hodorovich et al., 2023
|
|
embryonic cranial skeleton morphogenesis disrupted, abnormal
|
chd7ncu101/+ (TL)
|
standard conditions
|
Fig. 1
from Hodorovich et al., 2023
|
|
whole organism decreased life span, abnormal
|
chd7ncu101/+ (TL)
|
standard conditions
|
Fig. 1
from Hodorovich et al., 2023
|
|
otolith morphology, abnormal
|
chd7ncu101/+ (TL)
|
standard conditions
|
Fig. 1
from Hodorovich et al., 2023
|
|
sagitta decreased amount, abnormal
|
chd7ncu101/+ (TL)
|
standard conditions
|
Fig. 1
from Hodorovich et al., 2023
|